期刊文献+

肺癌分子标志物的研究进展及转化应用 被引量:5

Research progress and translational application of molecular markers of lung cancer
下载PDF
导出
摘要 转化医学促进了分子生物学等基础医学发展,改变了医学模式。其目的是将医学的基础研究成果快速有效的转化为用于临床的技术和药物,为医学知识服务临床铺平道路。随着肿瘤分子生物学的研究进展,越来越多的分子生物标志物被发现并用于肺癌的诊断、治疗、预后和疗效监测。本文将肺癌分子标志物的研究进展和在转化方面的应用进行综述。 The translational medicine has improved the development of basic medicine such as molecular biology and has changed the medical model.The aim of translational medicine is to translate the basic research achievement of medical biology into technologies and drugs for application quickly and effectively.With the research progress of molecular biology of lung cancer,more molecular biomarkers have been found and used for tumor diagnosis,treatment,prognosis and curative effect surveillance.The research and application of lung cancer molecular markers are summarized as follows.
作者 崔国辉 胡海 Cui Guohui;Hu Hai(Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation,Sun Yat-Sen Memorial Hospital,Sun Yat-Sen University,Guangzhou 510120,Guangdong,China)
出处 《生物医学转化》 2020年第1期79-85,共7页 Biomedical transformation
基金 国家自然科学基金(面上项目:81672738,重点项目:81730077)。
关键词 肺癌 分子标志物 转化医学 Lung cancer Biomarker Translational medicine
  • 相关文献

参考文献1

二级参考文献44

  • 1Jemal A,Siegel R,Xu J,et.al.Cancer statistics,2010[J].CA Cancer J Clin,2010,60(5):277-300.
  • 2Molina J R,Yang P,Cassivi S D,et al.Non-small cell lung cancer:epidemiology,risk factors,treatment,and survivorship[J].Mayo Clin Proc,2008,83(5):584-594.
  • 3Alberg A J,Ford J G,Samet J M,et al.Epidemiology of lung cancer:ACCP evidence-based clinical practice guidelines[J].Chest,2007,132(3 Suppl):29S-55S.
  • 4Paesmans M,Sculier J P,Libert P,et al.Prognostic factors for survival in advanced non-small-cell lung cancer:univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patient.The European Lung Cancer Working Partys[J].J Clin Oncol,1995,13(5):1221-1230.
  • 5Donnem T,Bremnes R M,Busund L T,et.al.Gene expression assays as prognostic and predictive markers in early stage non-small cell lung cancer[J].J Thorac Dis,2012,4(2):212-213.
  • 6Osarogiagbon R U.Predicting survival of patients with resectable non-small cell lung cancer:Beyond TNM[J].J Thorac Dis,2012,4(2):214-216.
  • 7Hanagiri T,Sugaya M,Takenaka M,et.al.Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer[J].Lung Cancer,2011,74(1):112-117.
  • 8Gold P,Freedman S O.Specific carcinoembryonic antigens of the human digestive system[J].J Exp Med,1965,122(3):467-481.
  • 9Okada M,Nishio W,Sakamoto T,et al.Prognostic significance of perioperative serum carcinoembryonic antigen in non-small cell lung cancer:analysis of 1 000 consecutive resections for clinical stage I disease[J].Ann Thorac Surg,2004,78(1):216-221.
  • 10Lee J H,Chang J H.Diagnostic utility of serum and pleural fluid carcinoembryonic antigen,neuron-specific enolase,and cytokeratin 19 fragments in patients with effusions from primary lung cancer[J].Chest,2005,128(4):2298-2303.

共引文献7

同被引文献59

引证文献5

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部